Evaluating only Codiak BioSciences’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Market collapse.
Key Events Timeline
FOUNDING
Codiak BioSciences founded
LAYOFF
Market downturn forces cuts
SHUTDOWN
Bankruptcy: Codiak BioSciences ceases operations
Full Analysis
Free · no account needed
Documented cause
Codiak built the engEx platform to engineer exosomes as drug delivery vehicles, a genuinely innovative approach. After raising 300 million dollars and going public in 2020, multiple pipeline candidates failed to demonstrate sufficient clinical activity. The company filed for Chapter 11 in April 2023 and licensed its assets to pay creditors.
Lesson
“Novel drug delivery platforms require extensive de-risking before public markets. Exosomes were scientifically compelling but clinically unproven, and public investors bore the cost of that gap.”